Person Functionally Cured of HIV After Bone Marrow Transplant From Sibling

Why It Matters

The case proves that a genetically resistant sibling donor can eradicate HIV reservoirs, offering a proof‑of‑concept for curative approaches beyond conventional ART. It also highlights the steep risk‑benefit calculus that limits immediate clinical adoption.

Key Takeaways

• Sibling donor with CCR5Δ32 mutation enabled full engraftment
• No detectable HIV in blood, gut, or bone marrow
• Transplant risks limit therapy to patients with malignancies
• Study confirms sibling transplants reduce graft‑versus‑host concerns
• Long‑term monitoring needed to rule out viral rebound

Pulse Analysis

The latest report in *Nature Microbiology* marks a watershed moment for HIV cure research. While the “Berlin patient” and a handful of others achieved remission after receiving bone‑marrow from unrelated donors with the rare CCR5 Δ32 mutation, this new case demonstrates that a sibling donor can achieve the same result. The donor’s homozygous CCR5 Δ32 genotype prevents the virus from binding to T‑cells, and after transplantation the recipient’s immune system was repopulated with these resistant cells. Crucially, researchers detected no HIV in peripheral blood, gut mucosa, or bone marrow—sites that typically harbor latent virus—suggesting a true eradication of the viral reservoir.

From a scientific perspective, the study provides valuable insight into the mechanisms required for a durable cure. Full engraftment across multiple tissue compartments, especially the gut-associated lymphoid tissue, appears essential because it is a major reservoir for HIV. The findings also bolster the rationale for gene‑editing strategies, such as CRISPR‑Cas9, that aim to recreate the CCR5 Δ32 mutation in a patient’s own stem cells, potentially sidestepping the need for a donor altogether. Moreover, the data reinforce the importance of monitoring for viral rebound, as even minimal residual infected cells could reignite infection once antiretroviral therapy is halted.

Despite the excitement, the approach remains impractical for the broader HIV‑positive population. Bone‑marrow transplantation carries high mortality risk, severe infections, and graft‑versus‑host disease, making it viable only for patients already requiring a transplant for malignancy. The sibling match reduces immunologic incompatibility, yet the procedure’s toxicity far exceeds that of lifelong ART. Future research will likely focus on safer delivery methods—such as ex vivo gene‑edited autologous stem‑cell transplants—and on large‑scale clinical trials to assess durability and safety. Until then, the case serves as a compelling proof‑of‑concept rather than an imminent therapeutic option.